This is a big problem — it factored into the Food and Drug Administration's (FDA) decision to reject an MDMA-assisted therapy for PTSD this summer. These shortcomings need to be overcome for ...

That could help establish that the power of MDMA lies in its synergy with trauma-focused therapy. THE BASICS There are other flaws in the FDA’s reasoning, to the extent it can be inferred based ...

Emerson has been at the helm of Lykos since 2014 and has been involved in the development of its MDMA-based midomafetamine therapy for post-traumatic stress disorder (PTSD) for more than 20 years.

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of psychedelic pharmaceuticals specializing in natural psilocybin and MDMA, ...

MDMA-assisted therapy for post-traumatic stress disorder. This decision comes just months after advisors to the agency voted against evidence supporting MDMA therapy . The agency's decision was ...

to further study the effectiveness and safety of its psychedelic formulation. This would require additional funding as well as a number of... and (5) a full array of tailored corporate ...

Psychedelics are being tested as add-ons to psychotherapy, but in trials, there's little detail about how the therapy is actually conducted, Dr. Albino Oliveira-Maia says.